Novartis AG Investigation
Company: Novartis AG
Ticker: (NYSE) NVS
How to Check Whether You May Be Eligible in the Novartis AG Investigation
Investigation Details
Novartis AG shares fell sharply on September 8, 2026, after the company announced two back-to-back Phase 3 trial failures. First, on Friday, September 4, 2026, Novartis announced pelacarsen failed to meet its primary endpoint in the Phase 3 HORIZON pioneering cardiovascular outcomes study. The drug trial was unsuccessful in demonstrating statistically significant reductions in cardiovascular events.
Following this, on Monday, September 8, 2026, Novartis announced its experimental drug del-desiran failed to meet its primary endpoint in the Phase 3 HARBOR trial for myotonic dystrophy type 1. The drug did not show a statistically significant improvement compared to a placebo in video hand-opening time.